199 results about "Parainfluenza virus" patented technology

The present invention relates to recombinant bovine parainfluenza virus (bPIV) cDNA or RNA which may be used to express heterologous gene products in appropriate host cell systems and/or to rescue negative strand RNA recombinant viruses that express, package, and/or present the heterologous gene product. In particular, the heterologous gene products include gene product of another species of PIV or from another negative strand RNA virus, including but not limited to, influenza virus, respiratory syncytial virus, human metapneumovirus and avian pneumovirus. The chimeric viruses and expression products may advantageously be used in vaccine formulations including vaccines against a broad range of pathogens and antigens.

The invention belongs to the technical fields of biochips and diagnostic reagents, and discloses a method for detecting various respiratory viruses, and primers and probes thereof. In the invention, nucleotide sequences of 14 respiratory viruses, namely adenovirus, human metapneumovirus, influenza virus A, influenza virus B, respiratory syncytial virus, bocavirus, rhinovirus, coronavirus (HKU1, NL63 and SARS), and parainfluenza virus (type I, type II, type III and type IV) are analyzed, and corresponding reverse transcription primers, PCR primers and specific probes are designed. Specific gene segments are amplified by reverse transcription and multiple asymmetric PCR methods; a fluorescence-coded microsphere group coupled with the virus specific probes and the PCR amplification product are incubated and hybridized by liquid phase chip technology; and finally the Bio-PlexTM200 is used for detection. The detection method has the advantages of high flux, high specificity and sensitivity, stable results and good repeatability, the detection method is easy to operate, and the detection speed is high.

The present invention relates to methods for broad spectrum prevention and treatment of viral respiratory infection. In particular, the present invention relates to methods for preventing, treating or ameliorating symptoms associated with respiratory syncytial virus (RSV), parainfluenza virus (PIV), and/or human metapneumovirus (hMPV) infection, the methods comprising administering to a subject an effective amount of one or more anti-RSV-antigen antibodies or antigen-binding fragments thereof, one or more anti-hMPV-antigen antibodies or antigen-binding fragments thereof, and/or one or more anti-PIV-antigen antibodies or antigen-binding fragments thereof. In certain embodiments, a certain serum titer of the anti-RSV-antigen antibodies, anti-PIV-antigen antibodies, and/or anti-hMPV-antigen antibodies or antigen-binding fragments thereof is achieved in said subject. In certain specific embodiments, the subject is human and, preferably, the anti-RSV-antigen antibody, anti-PIV-antigen antibody, and/or anti-hMPV-antigen antibodies are human or humanized. The present invention relates further to compositions comprising the anti-RSV-antigen antibodies, anti-PIV-antigen antibodies, and/or anti-hMPV-antigen antibodies or antigen-binding fragments thereof. The present invention also relates to detectable or diagnostic compositions comprising the one or more anti-RSV-antigen antibodies, anti-PIV-antigen antibodies, and/or anti-hMPV-antigen antibodies or antigen-binding fragments thereof and methods for detecting or diagnosing RSV, PIV and/or hMPV infection utilizing the compositions.

An immunization strategy to provide protection against disease caused by infection with a paramyxoviridae virus, specifically respiratory syncytial virus (RSV) and parainfluenza virus, is described. A priming intranasal administration of a recombinant virus expressing at least one RSV or PIV protein or immunogenic sequence there first is made to the host followed by a booster administration of at least one purified RSV or PIV protein or immunogenic fragment thereof, which may be adjuvanted with alum. This immunization strategy provides a safe and effective means of controlling RSV and PIV infections. The strategy leads to a stronger protective immune response than other strategies and to the induction of a more balanced Th-1/Th-2 type response than previously attained. Novel recombinant poxviruses are provided containing nucleic acid encoding a paramyxovirus protein or immunogenic fragment thereof is a non-essential region of the poxvirus genome, specifically NYVAC-F and ALVAC-F, which produce the F glycoprotein of RSV.

Chimeric parainfluenza viruses (PIVs) are provided that incorporate a PIV vector genome or antigenome modified to encode a chimeric glycoprotein incorporating one or more heterologous antigenic domains, fragments, or epitopes of a second, antigenically distinct HPIV. These chimeric viruses are infectious and attenuated in humans and other mammals and are useful in vaccine formulations for eliciting an immune responses against one or more PIVs, and, optionally against respiratory syncytial virus (RSV). Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric PIV genome or antigenome which includes a HPIV vector genome or antigenome combined or integrated with one or more heterologous genome segment(s) encoding one or more antigenic determinant(s) of a heterologous PIV to encode a chimeric glycoprotein. In preferred aspects of the invention, the chimeric virus is attenuated for use as a vaccine agent by additional mutations or nucleotide modifications introduced into the chimeric genome or antigenome.

The present invention provides infectious recombinant viral vectors (e.g., parainfluenza virus (PIV) and a respiratory syncytial virus (RSV) vectors) comprising a viral genome comprising a heterologous nucleic acid of interest. Also provided are pseudotyped recombinant viral vectors comprising (i) a viral envelope and (ii) a viral genome comprising heterologous nucleic acids of interest. The viral envelope comprises a structural protein selected from the group consisting of envelope proteins from PIV and/or RSV. Further provided are methods of delivering heterologous nucleic acids of interest into airway epithelial cells comprising introducing viral vectors of the present invention comprising nucleic acids of interest into airway epithelial cells so that the nucleic acids of interest are expressed therein.

Chimeric parainfluenza viruses (PIVs) incorporate a PIV vector genome or antigenome and one or more antigenic determinant(s) of a heterologous PIV or non-PIV pathogen. These chimeric viruses are infectious and attenuated in humans and other mammals and are useful in vaccine formulations for eliciting an immune responses against one or more PIVs, or against a PIV and non-PIV pathogen. Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric Ply genome or antigenome which includes a partial or complete PIV vector genome or antigenome combined or integrated with one or more heterologous gene(s) or genome segment(s) encoding antigenic determinant(s) of a heterologous PIV or non-PIV pathogen.

Chimeric parainfluenza viruses (PIVs) are provided that incorporate a PIV vector genome or antigenome and one or more antigenic determinant(s) of a heterologous PIV or non-PIV pathogen. These chimeric viruses are infectious and attenuated in humans and other mammals and are useful in vaccine formulations for eliciting and immune responses against one or more PIVs, or against a PIV and non-PIV pathogen. Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric PIV genome or antigenome which includes a partial or complete PIV vector genome or antigenome combined or integrated with one or more heterologous gene(s) or genome segment(s) encoding antigenic determinant(s) of a heterologous PIV or non-PIV pathogen. In preferred aspects of the invention, chimeric PIV incorporate a partial or complete human PIV vector genome or antigenome combined with one or more heterologous gene(s) or genome segment(s) from a heterologous PIV or non-PIV pathogen, wherein the chimeric virus is attenuated for use as a vaccine agent by any of a variety of mutations and nucleotide modifications introduced into the chimeric genome or antigenome.

Multimeric hybrid genes encoding the corresponding chimeric protein comprise a gene sequence coding for an antigenic region of a protein from a first pathogen linked to a gene sequence coding for an antigenic region of a protein from a second pathogen. The pathogens particularly are parainfluenza virus (PIV) and respiratory syncytial virus (RSV). A single recombinant immunogen is capable of protecting infants and similar susceptible individuals against diseases caused by both PIV and RSV.

A porous solid material for adsorbing and deactivating the viruses, especially the parainfluenza virus, is prepared from one of TiO2, ZrO2, SiO2 and Al2O3 or P2O5 or their mixture. It can be modified by one or more elements in the families VIII, Ib, IIb, or IIa.

Self-propagating, fusogenic blebs are produced from cells infected with a population of Venezuelan Equine Encephalitis virus replicon particles (VRP). The self-propagating, fusogenic nature of the blebs is derived from expression of heterologous genes encoding viral fusion proteins that are incorporated into the replication defective replicon particles. The resulting blebs can be harvested from supernatants of cells displaying severe cytopathic effects. The blebs are used to make immunogenic compositions and devise methods of immunizing mammals against paramyxoviruses such as parainfluenza virus type 3.

The present disclosure relates to a real-time fluorescence multiplex PCR primer probe for seven common respiratory system influenza virus pathogens and a kit. Seven influenza viruses are influenza A virus, influenza B virus, parainfluenza virus type I, parainfluenza virus type II, parainfluenza virus type III, respiratory syncytial virus and adenovirus. The present disclosure also provides a kit for multiplex fluorescence quantitative PCR detection of the seven influenza viruses, and the kit includes the primer probe set. The kit significantly improves the sensitivity, specificity, and simplicity of detection of the common respiratory system pathogens.

The invention belongs to the field of molecular biology, and relates to a hybridoma cell strain capable of secreting a CPIV3 antibody and an ELISA kit. A caprine parainfluenza virus 3 CPIV3 immunogen used in the invention is a CPIV3 JS2013 viral strain isolated clinically, and a hybridoma cell strain 2E6 is screened from an established hybridoma cell bank capable of secreting the CPIV3 antibody. The monoclonal antibody secreted by the hybridoma cell strain has the blocking effect, and is applied to the CPIV3 blocking ELISA kit. The CPIV3 blocking ELISA kit can specifically detect the antibody generated after the CPIV3 infection or caprine immunization. 212 caprine clinical serum samples are colleted, and the CPIV3 antibody in the serum is tested by the established blocking ELISA method and a neutralization test. Through the comparison between the result of the blocking ELISA method and the result of the neutralization test, the coincidence rate is 98.8%.

The invention relates to three reagent kits for detecting human parainfluenza viruses 1, 2, 3 type real-time fluorescence polymerase chain reaction, which respectively adopts a one-step method RT-PCR, a two-step method RT-PCR and a multicolor fluorescence method RT-PCR to distinguish types of the human parainfluenza viruses of multi-type specimens and fix an amount of the human parainfluenza viruses of the multi-type specimens. The detection methods of the reagent kits have simple operation, short consuming time and high sensitivity and specificity and can be extensively used in a plurality of fields, such as the auxiliary diagnosis of the infection of the human parainfluenza viruses, clinical medicine direction, epidemiology retrospective study, and the like.

Belonging to the molecular biology field, the invention relates to a primer set for respiratory tract infection pathogen detection, a rapid diagnostic kit and a detection method. The primer set can achieve one-time detection of the following 9 respiratory tract infection pathogens: influenza A virus, influenza B virus, respiratory syncytial virus, parainfluenza virus type I, parainfluenza virus type II and parainfluenza virus type III, adenovirus, mycoplasma pneumonia, legionella pneumonia, chlamydia pneumonia and human rhinovirus. The invention adopts solid phase recombinase-polymerase constant temperature gene amplification method to detect respiratory multiple infection pathogens. The primer set adopted by the invention for respiratory tract infection pathogen detection has strong specificity and high amplification efficiency, can effectively and rapidly detect the 9 pathogens simultaneously, and realizes multiplex detection.

The invention discloses a double-fluorescent PCR detection primer, a probe, reaction liquid and a kit capable of rapidly detecting 16 pathogens of the respiratory tract. The kit comprises pre-subpackaged PCR reaction liquid, RT-PCR enzyme, a positive quality control product and a negative quality control product, wherein the pre-subpackaged PCR reaction liquid is provided with a primer and a TaqMan probe for detecting at least two of the following pathogens: respiratory syncytial virus, enterovirus, coronavirus NL63, coronavirus HKU1, coronavirus 229E, coronavirus OC43, parainfluenza virus type I, parainfluenza virus type II, rhinovirus, parainfluenza virus type III, human bocavirus, human metapneumovirus, mycoplasma pneumoniae, chlamydia pneumoniae, adenovirus and legionella pneumophila. The kit is convenient to operate, and can be used for at most screening 16 syndrome pathogens of the respiratory tract within 2 hours, so that the detection time and cost are greatly saved. The kit has the greatest advantages of simplicity in operation and strong practicability, and can be easily popularized in laboratories of the ports.